456 related articles for article (PubMed ID: 9259410)
21. MET increases the sensitivity of gefitinib-resistant cells to SN-38, an active metabolite of irinotecan, by up-regulating the topoisomerase I activity.
Sakai A; Kasahara K; Ohmori T; Kimura H; Sone T; Fujimura M; Nakao S
J Thorac Oncol; 2012 Sep; 7(9):1337-44. PubMed ID: 22722827
[TBL] [Abstract][Full Text] [Related]
22. DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
Rowinsky EK; Johnson TR; Geyer CE; Hammond LA; Eckhardt SG; Drengler R; Smetzer L; Coyle J; Rizzo J; Schwartz G; Tolcher A; Von Hoff DD; De Jager RL
J Clin Oncol; 2000 Sep; 18(17):3151-63. PubMed ID: 10963644
[TBL] [Abstract][Full Text] [Related]
23. Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignancies.
Braybrooke JP; Boven E; Bates NP; Ruijter R; Dobbs N; Cheverton PD; Pinedo HM; Talbot DC
Ann Oncol; 2003 Jun; 14(6):913-21. PubMed ID: 12796030
[TBL] [Abstract][Full Text] [Related]
24. Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance.
Van Hattum AH; Schlüper HM; Hausheer FH; Pinedo HM; Boven E
Int J Cancer; 2002 Jul; 100(1):22-9. PubMed ID: 12115582
[TBL] [Abstract][Full Text] [Related]
25. Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells.
Nakatomi K; Yoshikawa M; Oka M; Ikegami Y; Hayasaka S; Sano K; Shiozawa K; Kawabata S; Soda H; Ishikawa T; Tanabe S; Kohno S
Biochem Biophys Res Commun; 2001 Nov; 288(4):827-32. PubMed ID: 11688982
[TBL] [Abstract][Full Text] [Related]
26. The topoisomerase I inhibitor DX-8951f is active in a severe combined immunodeficient mouse model of human acute myelogenous leukemia.
Vey N; Giles FJ; Kantarjian H; Smith TL; Beran M; Jeha S
Clin Cancer Res; 2000 Feb; 6(2):731-6. PubMed ID: 10690560
[TBL] [Abstract][Full Text] [Related]
27. Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors.
McDonald AC; Brown R
Br J Cancer; 1998 Sep; 78(6):745-51. PubMed ID: 9743293
[TBL] [Abstract][Full Text] [Related]
28. Topoisomerase I inhibitors. An overview of the camptothecin analogs.
Burris HA; Fields SM
Hematol Oncol Clin North Am; 1994 Apr; 8(2):333-55. PubMed ID: 8040144
[TBL] [Abstract][Full Text] [Related]
29. Modulation of camptothecin analogs in the treatment of cancer: a review.
Kehrer DF; Soepenberg O; Loos WJ; Verweij J; Sparreboom A
Anticancer Drugs; 2001 Feb; 12(2):89-105. PubMed ID: 11261892
[TBL] [Abstract][Full Text] [Related]
30. DX-8951f: summary of phase I clinical trials.
De Jager R; Cheverton P; Tamanoi K; Coyle J; Ducharme M; Sakamoto N; Satomi M; Suzuki M;
Ann N Y Acad Sci; 2000; 922():260-73. PubMed ID: 11193901
[TBL] [Abstract][Full Text] [Related]
31. O(6)-methylguanine-DNA methyltransferase (MGMT) as a determinant of resistance to camptothecin derivatives.
Okamoto R; Takano H; Okamura T; Park JS; Tanimoto K; Sekikawa T; Yamamoto W; Sparreboom A; Verweij J; Nishiyama M
Jpn J Cancer Res; 2002 Jan; 93(1):93-102. PubMed ID: 11802813
[TBL] [Abstract][Full Text] [Related]
32. Novel mutation of topoisomerase I in rendering cells resistant to camptothecin.
Chang JY; Liu JF; Juang SH; Liu TW; Chen LT
Cancer Res; 2002 Jul; 62(13):3716-21. PubMed ID: 12097280
[TBL] [Abstract][Full Text] [Related]
33. In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues.
Emerson DL; Besterman JM; Brown HR; Evans MG; Leitner PP; Luzzio MJ; Shaffer JE; Sternbach DD; Uehling D; Vuong A
Cancer Res; 1995 Feb; 55(3):603-9. PubMed ID: 7834631
[TBL] [Abstract][Full Text] [Related]
34. Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations.
Yang CJ; Horton JK; Cowan KH; Schneider E
Cancer Res; 1995 Sep; 55(18):4004-9. PubMed ID: 7664272
[TBL] [Abstract][Full Text] [Related]
35. Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor.
Lee JH; Lee JM; Kim JK; Ahn SK; Lee SJ; Kim MY; Jew SS; Park JG; Hong CI
Arch Pharm Res; 1998 Oct; 21(5):581-90. PubMed ID: 9875499
[TBL] [Abstract][Full Text] [Related]
36. Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia.
Giles FJ; Cortes JE; Thomas DA; Garcia-Manero G; Faderl S; Jeha S; De Jager RL; Kantarjian HM
Clin Cancer Res; 2002 Jul; 8(7):2134-41. PubMed ID: 12114413
[TBL] [Abstract][Full Text] [Related]
37. Combination of SN-38 with gefitinib or imatinib overcomes SN-38-resistant small-cell lung cancer cells.
Takigawa N; Takeyama M; Kozuki T; Shibayama T; Hisamoto A; Kiura K; Tada A; Hotta K; Umemura S; Ohashi K; Fujiwara Y; Takata S; Ichihara E; Osawa M; Tabata M; Tanimoto M; Takahashi K
Oncol Rep; 2007 May; 17(5):983-7. PubMed ID: 17390033
[TBL] [Abstract][Full Text] [Related]
38. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan.
Mathijssen RH; Loos WJ; Verweij J; Sparreboom A
Curr Cancer Drug Targets; 2002 Jun; 2(2):103-23. PubMed ID: 12188913
[TBL] [Abstract][Full Text] [Related]
39. A novel B-ring modified homocamptothecin, 12-Cl-hCPT, showing antiproliferative and topoisomerase I inhibitory activities superior to SN-38.
Bailly C; Laine W; Baldeyrou B; Demarquay D; Huchet M; Coulomb H; Lanco C; Lavergne O; Bigg DC
Anticancer Drug Des; 2001 Feb; 16(1):27-36. PubMed ID: 11762642
[TBL] [Abstract][Full Text] [Related]
40. 7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials.
Saijo N; Nishio K; Kubota N; Kanzawa F; Shinkai T; Karato A; Sasaki Y; Eguchi K; Tamura T; Ohe Y
Cancer Chemother Pharmacol; 1994; 34 Suppl():S112-7. PubMed ID: 8070019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
